Click Here to
News, Updates,
& More
Stay Up
to Date
Chemotherapy-induced febrile neutropenia (CIFN) is a life-threatening, costly complication that may develop in patients with cancer after receiving myelosuppressive chemotherapy. In 1991, filgrastim (Neupogen) was approved for the treatment of patients with CIFN, because it stimulates the production of neutrophils, which potentially treats and prevents febrile neutropenia.
The following briefs provide updates on new FDA approvals and indications to help hematology and oncology pharmacists keep up with new information regarding drugs that are coming to market for the management of patients with cancer.
Cetuximab and panitumumab, monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), are an integral component in the management of patients with metastatic colorectal cancer (mCRC), specifically those with KRAS wild-type tumors.

Results 1 - 4 of 4